Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Appointed director

PROLUNG INC (LUNG) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
04/17/2023 10-K Annual Report for the period ended December 31, 2022
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/28/2022 8-K Quarterly results
05/23/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/17/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/04/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/03/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/03/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/15/2022 10-K Annual Report for the period ended December 31, 2021
03/08/2022 8-K Quarterly results
02/02/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "About IONIQ Sciences, Inc. IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics or bioimpedance technology and Artificial Intelligence . IONIQ Science’ s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. For further information about IONIQ Sciences, Inc., please contact: Andy Robertson | 1-801-736-0729 | [email protected] IONIQ Sciences, Vice President of Business Development IONIQ Sciences, Inc. 350 W. 800 N., Suite 214 S..."
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
10/07/2021 8-K Appointed a new director
Docs: "IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake City, UT, October 7, 2021 – IONIQ Sciences, Inc. , is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today IONIQ Sciences announced the appointment of Aaron B. Dorny to its Board of Directors. Mr. Jared Bauer, CEO, stated, “On behalf of the IONIQ Sciences Board of Directors, we are delighted to welcome Mr. Dorny to the Board. We believe that his deep understanding of our life science business and proven financial acumen with companies large and small will greatly help us achieve our goals. Mr. Dorny’ s contributions to our company over the pas..."
08/16/2021 10-Q Quarterly Report for the period ended June 30, 2021
07/14/2021 8-K Quarterly results
06/02/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/28/2021 8-K Quarterly results
05/25/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/25/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/24/2021 10-Q Quarterly Report for the period ended March 31, 2021
05/14/2021 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/03/2021 10-K Annual Report for the period ended December 31, 2020
04/20/2021 GN Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021
03/15/2021 10-Q Quarterly Report for the period ended September 30, 2020
12/21/2020 D Form D - Notice of Exempt Offering of Securities:
12/08/2020 GN Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth
11/30/2020 GN Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
11/03/2020 GN Pulmonx to Present at Upcoming Investor Conferences
11/02/2020 GN Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD)
10/05/2020 GN Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
09/30/2020 GN Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
09/16/2020 10-Q Quarterly Report for the period ended June 30, 2020
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy